Remission and Recovery in Mental Health

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Psychiatric Diseases".

Deadline for manuscript submissions: closed (15 June 2022) | Viewed by 6008

Special Issue Editors

Department of Clinical and Experimental Medicine, Psychiatry Unit, University of Catania, Via Santa Sofia 78, 95123 Catania, Italy
Interests: psychiatry; autism spectrum disorder; neurodevelopmental disorders; social cognition; psychosis; complementary therapies
Department of Clinical and Experimental Medicine, Psychiatry Unit, University of Catania, Via Santa Sofia 78, 95123 Catania, Italy
Interests: bipolar disorder; neuroplasticity; depression; addiction
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Evidence has shown that over their life course, around 5% of adults suffer from a serious mental disorder, such as schizophrenia or affective disorders. Patients with mental health problems frequently fluctuate between periods of full-blown symptomatology and periods of remission. Nevertheless, only a fraction of these patients reaches so-called “recovery”, a sustained period marked by the absence of clinically meaningful symptomatology, in which patients can progress live autonomously and participate in everyday activities, routines, employment, and education.

The Special Issue “Remission and Recovery in Mental Health” aims to encourage debate around the concepts of remission and recovery and to help in improving the quality and personalization of care in psychiatry. Authors are invited to submit cutting-edge original research, short reports, systematic and non-systematic reviews, as well as commentaries, addressing (but not limited to) the following topics: factors associated with symptoms remission and recovery in major mental disorders; rehabilitation programs to foster full functional recovery; efficacy of pharmacological and psychosocial treatments to prevent the relapse of psychiatric symptoms; unmet needs and patients’ preferences. First-person accounts from people who suffer or have suffered from a mental disorder are also of great interest. 

Dr. Laura Fusar-Poli
Dr. Carmen Concerto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • major depression
  • schizophrenia
  • outcome
  • functioning
  • recovery
  • remission
  • rehabilitation
  • discontinuation
  • unmet needs
  • quality of life

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 1643 KiB  
Article
Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in an Italian Sample of Patients with Stable Schizophrenia and Bipolar Spectrum Disorders
by Alessandro Rodolico, Carmen Concerto, Alessia Ciancio, Spyridon Siafis, Laura Fusar-Poli, Carla Benedicta Romano, Elisa Vita Scavo, Antonino Petralia, Salvatore Salomone, Maria Salvina Signorelli, Stefan Leucht and Eugenio Aguglia
Brain Sci. 2022, 12(7), 891; https://0-doi-org.brum.beds.ac.uk/10.3390/brainsci12070891 - 07 Jul 2022
Cited by 1 | Viewed by 1993
Abstract
Antipsychotics are a class of psychotropic drugs that improve psychotic symptoms and reduce relapse risk. However, they may cause side effects (SE) that impact patients’ quality of life and psychosocial functioning. Therefore, there is a need for practical tools to identify them and [...] Read more.
Antipsychotics are a class of psychotropic drugs that improve psychotic symptoms and reduce relapse risk. However, they may cause side effects (SE) that impact patients’ quality of life and psychosocial functioning. Therefore, there is a need for practical tools to identify them and possibly intervene. The objective of the present study was to translate into Italian the Glasgow Antipsychotic Side Effect Scale (GASS), which is suggested as the questionnaire of choice to collect SE reported by patients treated with antipsychotics. We administered the GASS and the Udvalg for Kliniske Undersøgelser (UKU) SE scale—which is considered the gold standard—to 100 stable patients with schizophrenia and bipolar spectrum disorders. We measured the structural validity, internal consistency, concurrent criterion validity, construct validity, and clinical feasibility. GASS was characterized by modest structural validity and good internal consistency. The binary correlations concerning the presence of specific symptoms investigated with the GASS and the UKU were strong or relatively strong for only half of them. The GASS total scale score was inversely related to patients’ quality of life and psychosocial functioning. The GASS is useful to briefly assess the burden of antipsychotic SE (~5 min) but is not optimal in identifying them. Full article
(This article belongs to the Special Issue Remission and Recovery in Mental Health)
Show Figures

Figure 1

Review

Jump to: Research

11 pages, 270 KiB  
Review
Mixed Depression: A Mini-Review to Guide Clinical Practice and Future Research Developments
by Antimo Natale, Ludovico Mineo, Laura Fusar-Poli, Andrea Aguglia, Alessandro Rodolico, Massimo Tusconi, Andrea Amerio, Gianluca Serafini, Mario Amore and Eugenio Aguglia
Brain Sci. 2022, 12(1), 92; https://0-doi-org.brum.beds.ac.uk/10.3390/brainsci12010092 - 11 Jan 2022
Cited by 4 | Viewed by 3502
Abstract
The debate on mixed states (MS) has been intense for decades. However, several points remain controversial from a nosographic, diagnostic, and therapeutic point of view. The different perspectives that have emerged over the years have turned into a large, but heterogeneous, literature body. [...] Read more.
The debate on mixed states (MS) has been intense for decades. However, several points remain controversial from a nosographic, diagnostic, and therapeutic point of view. The different perspectives that have emerged over the years have turned into a large, but heterogeneous, literature body. The present review aims to summarize the evidence on MS, with a particular focus on mixed depression (MxD), in order to provide a guide for clinicians and encourage the development of future research on the topic. First, we review the history of MS, focusing on their different interpretations and categorizations over the centuries. In this section, we also report alternative models to traditional nosography. Second, we describe the main clinical features of MxD and list the most reliable assessment tools. Finally, we summarize the recommendations provided by the main international guidelines for the treatment of MxD. Our review highlights that the different conceptualizations of MS and MxD, the variability of clinical pictures, and the heterogeneous response to pharmacological treatment make MxD a real challenge for clinicians. Further studies are needed to better characterize the phenotypes of patients with MxD to help clinicians in the management of this delicate condition. Full article
(This article belongs to the Special Issue Remission and Recovery in Mental Health)
Back to TopTop